Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein e genotype in alzheimer patients

Dementia and Geriatric Cognitive Disorders

Volumn 34, Issue 3-4, 2012, Pages 167-173

  Han, Hyun Jeong ^a   Kim, Byeong C ^c   Lee, Jun Young ^d   Ryu, Seung Ho ^e   Na, Hae Ri ^g   Yoon, Soo Jin ^h   Park, Hyun Young ⁱ   Shin, Joon Hyun ^j   Cho, Soo Jin ^j   Yi, Hyon Ah ^k   Choi, Mun Seong ^l   Heo, Jae Hyeok ^f   Park, Kyung Won ^m   Kim, Kwang K ^b   Choi, Seong Hye ⁿ  

^a Kwandong University College of Medicine   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

^f Seoul Medical Center   (South Korea)

^g Bobath Memorial Hospital   (South Korea)

^h Eulji University   (South Korea)

ⁱ Wonkwang University   (South Korea)

^j Hallym University College of Medicine   (South Korea)

^k Keimyung University   (South Korea)

^l Maryknoll Hospital   (South Korea)

^m Dong A University College of Medicine   (South Korea)

ⁿ Inha University School of Medicine   (South Korea)

more..

Author keywords

Activities of daily living; Alzheimer's disease; Apolipoprotein E genotype; Memantine; Rivastigmine transdermal patch

Indexed keywords

APOLIPOPROTEIN E4; MEMANTINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; PHENYLCARBAMATES; PROSPECTIVE STUDIES; TRANSDERMAL PATCH;

EID: 84867214027     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000342927     Document Type: Article

References (37)

1. Katzman R: Alzheimer's disease. N Engl J Med 1986;314:964-973.
2. Slooter AJ, Cruts M, Kalmijin S, Hofman A, Breteler MM, van Broeckhoven C, van Duijin CM: Risk estimates of dementia by apolipoprotein E genotypes from a populationbased incidence study: the Rotterdam study. Arch Neurol 1998;55:964-968.
3. Masullo C, Daniele A, Seripa D, Filippini V, Gravina C, Carbone G, Gainotti G, Fazio VM: Apolipoprotein E genotype in sporadic early-and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:121-125.
4. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH: Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease: utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-511.
5. Holzman DM, Fagan AM, Mackey B, Tenkoya T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT: Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease Model. Ann Neurol 2000;47:739-747.
6. Huang Y: Apolipoprotein E and Alzheimer disease. Neurology 2006;66(suppl 1):S79-S85.
7. Lehmann DJ, William J, McBroom J, Smith AD: Using meta-analysis to explain the diversity of results in genetic studies of late onset Alzheimer's disease and to identify highrisk subgroups. Neuroscience 2001;108: 541-554.
8. Farlow M, Lane R, Kudaravalli S, He Y: Differential qualitative response to rivastigmine in APOE ε4 carriers and noncarriers. Pharmacogenomics J 2004;4:332-335.
9. Blesa R, Aguilar M, Casanova JP, Boada M, Martinez S, Alom J, de la Hoz CH, Sancho J, Femansez O, Gil-Neciga E, Masso JF: Relationship between the efficacy of rivastigmine and apolipoprotein E (ε4) in patients with mild to moderately severe Alzheimer's disease. Alzheimer Dis Assoc Disord 2006; 20:248-254.
10. Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, Lee JH: Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin 2011;27:1375-1383.
11. McKhan G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. Folstein MF, Folstein SE, McHugh PR: Minimental state: a practical method for grading the cognitive state of patient for the clinician. J Psychiatr Res 1975;12:189-198.
13. Kang Y, Na DL, Hahn S: A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-307.
14. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
15. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
16. Kang SJ, Choi SH, Lee BH, Jeong Y, Hahn DS, Han IW, Cummings JL, Na DL: Caregiver-Administrated Neuropsychiatric Inventory (CGA-NPI). J Geriatr Psychiatry Neurol 2004;17:32-35.
17. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
18. Choi SH, Na DL, Lee BH, Hahn DS, Jeong JH, Yoon SJ, Yoo KH, Ha CK, Han IW, Dementia Research Group: Estimating the validity of the Korean version of expanded Clinical Dementia Rating (CDR) scale. J Korean Neurol Assoc 2001;19:585-591.
19. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(suppl 2): S33-S39.
20. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S: Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci 1996;802:101-110.
21. Rigaud AD, Traikov L, Caputo L, Guelfi MC, Latour F, Couderc R, Moulin F, de Rotro J, Forette F, Boller F: The apolipoprotein E epsilonallele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol 2000;7:255-258.
22. Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C, Masullo C: Apolipoprotein E ε4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20: 254-261.
23. Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC, Park MY: Effects of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:445-450.
24. Kanaya K, Abe S, Sakai M, Fujii H, Iwamoto T: Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype. Geriatr Gerontol Int 2010;10:25-31.
25. Aerssens J, Raeymaekers P, Lilienfield S, Geerts H, Konings F, Parys W: APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12:69-77.
26. Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S: Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010;25:419-426.
27. Porsteinsson AP, Grossberg GT, Mintzer J, Loin JT: Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5: 83-89.
28. Wilcock GK, Ballard CG, Cooper JA, Loft H: Mematine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-348.
29. Kalapatapu RK, Neuroschl JA: Update on neuropsychiatric symptoms of dementia: evaluation and management. Geriatrics 2009;64:20-26.
30. Cummings JL, Schneider E, Tariot PN, Graham SM, Mematine MEM-MD-02 Study Group: Behavioral effects of memantine on Alzheimer's disease patients receiving donepezil treatment. Neurology 2006;67:57-63.
31. Ye S, Huang Y, Mullendorff K, Dong I, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW: Apolipoprotein (Apo) E4 enhances amyloid β-peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci USA 2005;102:18700-18705.
32. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-307.
33. Mori F, Lai CC, Fusi F, Giacobini E: Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995; 6:633-636.
34. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate to severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
35. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004;21:317-324.
36. Lopez OL, Becker JT, Whahed AS, Saxton JA, Sweet R, Wolk DA, Klunk W, Dekosky ST: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2009;80:600-607.
37. Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT: Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry 2011;26:356-363.